CLASSYS Inc. Overview
CLASSYS is South Korea's largest listed energy-based aesthetic device (EBD) company by market capitalisation and profitability. It runs a "razor-and-blade" model: it installs high-intensity focused ultrasound (HIFU), monopolar radiofrequency (RF), microneedle RF (MNRF) and laser platforms in clinics, then sells high-margin, procedure-linked cartridges and tips. Its flagship HIFU franchise, Shurink, sold abroad as Ultraformer, and its monopolar RF system Volnewmer, sold in the US as Everesse, have built an installed base of more than 48,000 cumulative units since founding (IR Book 2Q26). The company has posted operating margins near 50% for five consecutive years. Bain Capital has controlled it since 2022. Since then it has merged with Ilooda (October 2024) to add MNRF and lasers, bought its Brazilian distributor MedSystems (2025–26), and begun moving to direct sales in Japan and Latin America. It now faces a margin reset from direct-distribution costs, a slowing Korean market, a cut to 2026 guidance, a stock down more than 60% from its high, and an unresolved private-equity exit.
What the company does
CLASSYS designs, manufactures and sells non-invasive and minimally invasive aesthetic medical devices, together with their consumables, to dermatology and plastic-surgery clinics and aesthetic practices. It also sells home-use beauty devices and cosmetics. After merging with Ilooda in October 2024, management describes the portfolio as covering the four main EBD technology classes: HIFU, monopolar RF, MNRF and lasers (Source: Classys merger completion release, Metro Seoul / Medigate News, 2–4 Oct 2024). The company's 2Q26 disclosure says it sells in more than 80 countries, though press releases in 2025 cited 60–70. The difference reflects partner coverage versus active markets (Source: Quartr summary of 1H26 half-year report; Wanted company profile; Wikipedia).
Business and revenue model
| Revenue stream (FY2025, KRW Bn) | Amount | % of revenue | Nature |
|---|---|---|---|
| Devices | 174.0 | 51.7 | Capital equipment, one-off |
| Consumables | 154.6 | 45.9 | Recurring, procedure-linked |
| Homecare (B2C devices) | 7.3 | 2.2 | Consumer product |
| Rentals (Korea) | 0.9 | 0.3 | Device leasing |
| Total | 336.8 | 100.0 | — |
The model is an installed-base platform. A device sale carries a one-off margin and establishes the clinic relationship. Each procedure then consumes a proprietary cartridge (HIFU) or tip (RF/MNRF), which produces recurring revenue. Management has said gross margin approaches 80% when the consumables mix exceeds 50% (Source: Hankyung, 8 May 2024, 1Q24 results commentary).
Source: IR Book 4Q25, "Sales by Brand" table, FY2025. Percentages are derived.
There is no meaningful subscription or licensing revenue. From 2Q26 the company also books commission revenue in Japan as it moves to direct sales there (Source: IR Book 2Q26, gross-profit commentary).
Value-chain position
Historically CLASSYS was a designer-manufacturer that exported through exclusive national distributors, such as MedSystems in Brazil, Cartessa Aesthetics in the US and partners in Thailand. It is now integrating forward into distribution:
Brazil, Colombia, Argentina: acquired the MedSystems group (77.5% of JL Health plus 100% of the Colombian and Argentine distributors). The deal was agreed in October 2025 and consolidated from March 2026.
Japan: Classys Japan was established in 2024. Management targets a 100% transition to direct sales (IR Book 2Q26, 2H26 initiatives).
Korea: sells direct to clinics.
US and Europe: distributor-led. Cartessa handles the US.
Customers and end-markets
Customers are dermatology clinics, plastic-surgery clinics, aesthetic chains and medspas. In Brazil they include more than 15,000 hospitals and aesthetic spas served by MedSystems (MedSystems IR Book, Oct 2025). Retail and e-commerce consumers buy the homecare line. The end market is non-surgical lifting, tightening, skin rejuvenation and vascular/pigment treatment. Demand comes from consumer spending on "well-aging" procedures, medical tourism (inbound tourism to Korea is cited as a consumables driver by LS Securities, June 2025) and the global shift toward minimally invasive procedures.
Company's self-description and independent characterisation
The company describes itself as a global medical aesthetics platform with end-to-end EBD solutions. It claims to be the only company able to offer personalised, combined-procedure experiences across all major energy modalities (paraphrasing CEO Yoon Jun-oh, Asia Economy, 12 Oct 2026). It sets a target of US$1 billion in revenue by 2030 (IR materials; Edaily, Oct 2026).
Independent characterisation: CLASSYS is a highly cash-generative, mid-sized device company. Its economics resemble a consumables franchise: gross margin 77–79% and EBITDA margin 53–55% in FY2024–25. That profile is now being diluted on purpose by vertical integration into lower-margin distribution (MedSystems EBITDA margin in the low teens; BizWatch, Jan 2026) and by heavier spending on marketing, R&D and senior hires. The strategic question is whether direct control of channels in Latin America and Japan, plus entry into the US and China, can sustain the 30–40% growth that historically justified premium multiples. The stock's de-rating in 2026 shows the market doubts it.
Strategy
Stated long-term targets
At the Ilooda merger (Oct 2024) the company set 2030 targets (Medigate News, 4 Oct 2024):
-
Revenue of at least US$1 bn and an operating margin of at least 50% by 2030.
-
Five blockbuster-class platforms.
-
Overseas procedure volume per platform growing at least 5% a year.
-
No. 1 installed base in lifting and tightening devices in the US and China.
-
Direct operations in five strategic countries.
-
A 20% cut in device and consumable unit costs.
Brazilian coverage of the July 2026 CEO appointment described the target as about US$730 m with a 50% margin by 2030 (Times Brasil, 15 Jul 2026). This is probably a currency conversion of a KRW 1 trillion target. Korean sources and the Oct 2026 CCO announcement still cite US$1 bn. The difference is unresolved.
2026 strategic pillars (IR Book 4Q25 guidance slide; paraphrased)
-
Direct operations in Brazil, Latin America and Japan to improve profit structure: recognise revenue at end-user prices, capture the distributor margin, and strengthen training and service for customer lock-in.
-
Scaled growth in the US and Europe: wider European adoption and RF leadership in the US with Quadessy and Everesse. US approval of Ultraformer is expected in 2027.
-
Volnewmer/Everesse as the "next global flagship": annual unit sales above 2,000, succeeding Ultraformer, which sells more than 3,000 units a year.
-
Quadessy and lasers: more than 1,000 Quadessy units a year; establish it as the main MNRF expansion driver.
-
Korea: lead combination-procedure trends across Volnewmer, Shurink Universe and Fortra.
-
Home beauty: expand retail distribution for Shrink Home Lift-to-Glow.
-
China market entry: distributor agreement signed; rollout follows Volnewmer approval.
2H26 initiatives (IR Book 2Q26)
Global: keep growth momentum and accelerate China entry.
Korea: drive new-product sales, strengthen combination-treatment marketing and package promotions.
Japan: stabilise direct sales, complete the 100% move to direct, and expand network-clinic coverage.
South America: prioritise a top-line turnaround through B2B2C marketing.
New-management agenda (Jul–Oct 2026)
CEO Yoon's four stated priorities (SmartToday; Medical Times, 15 Jul 2026):
-
Faster global expansion using global expertise.
-
Next-generation products, services and platforms that combine AI, software and data. The goal is "first-of-kind" products built on the company's energy-device technology and accumulated procedure data.
-
A stronger business portfolio and new growth engines.
-
Better company-wide management systems and execution.
Supporting moves: the GTM Center (Jul 2026), the CTO hire (Aug 2026) and the CCO hire (Oct 2026). The CCO's remit covers entry and growth in the Americas, China and Europe, leadership in Korea, and data- and AI-driven go-to-market operations.
ESG and cost programmes
-
Cost: 20% unit-cost reduction target (2024), plus cost-saving and unit-cost initiatives cited in 3Q25 commentary.
-
ESG commitments: none identified.
Medium-term financial guidance
| Guidance item | Original | Revised | Source |
|---|---|---|---|
| FY2025 revenue | KRW 340–360 bn (raised after 1Q25) | Actual KRW 336.8 bn, just below the low end | IR Book 1Q25; IR Book 4Q25 |
| FY2026 revenue | KRW 470–510 bn (midpoint 490) | KRW 445 bn (12 Aug 2026) | IR Book 4Q25; Edaily, Aug 2026 |
| 2030 revenue | at least US$1 bn | unchanged | Asia Economy, Oct 2026 |
| 2030 operating margin | at least 50% | unchanged | Medigate News, Oct 2024 |
The revised KRW 445 bn guidance implies 2H26 revenue of about KRW 252.3 bn, up about 43% on 2H25 (KRW 176.4 bn). That requires a sharp step-up from the 1H26 run rate (derived).
Products & Services
Prices for devices and consumables are not publicly disclosed. Launch years are given only where a source confirms them.
HIFU platforms (lifting and tightening)
| Product | Description and capabilities | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Shurink (Korea) / Ultraformer III (export) | First-generation flagship HIFU. Delivers focused ultrasound at set dermal and subdermal depths to create thermal coagulation points that stimulate collagen. Uses cartridges. | Dermatology and aesthetic clinics | Korean installed base 3,700+ (end-2025). | Shurink series cumulative global sales exceeded 19,000 units by Aug 2025 (Venture Square, Aug 2025) |
| Shurink Universe (Korea) / Ultraformer MPT (export) | Second-generation HIFU adding an "MPT" micro-pulsed mode alongside conventional mode, for faster, more comfortable treatment. Core growth driver of 2023–25. | Clinics; aesthetic chains | Korean launch around 2022. CE certification Aug 2025. | Korea installed base 2,700+; ex-Korea Ultraformer installed base 14,000+ (IR Book 4Q25). Record overseas quarterly sales in 2Q26. |
| Ultraformer MPT PLUS | Next-generation HIFU being tested in a US pivotal study for submental and neck lifting | US physicians (FDA pathway) | In clinical trial | FDA IDE G250041. Multicentre, randomized, triple-masked non-inferiority trial against Merz's Ulthera System (ClinicalTrials.gov NCT07229430, recruiting). Company targets US approval in 2027; Daishin expects 2028. |
Monopolar RF
| Product | Description and capabilities | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Volnewmer (Korea, Asia, LatAm, EU) / EVERESSE (US) | Non-invasive monopolar RF tightening system with water-cooled tips. Positioned against Thermage. | Dermatology and plastic-surgery clinics; premium chains | Korea 2023. US FDA clearance about early 2024; US launch Oct–Nov 2024 via Cartessa. Taiwan TFDA Jul 2024. EU CE MDR May 2025. | Cumulative sales over 2,000 by Aug 2025. Installed base 2,200+ ex-Korea and 1,000+ Korea at end-2025. Management calls it the "next global flagship" with annual unit sales above 2,000. A completed non-inferiority trial compared it with Thermage CPT (NCT06657365); an elasticity pilot is also registered (NCT06816069). China launch expected after NMPA approval (Samsung Securities expects approval Dec 2026; Daishin expects launch 2027). |
Microneedle RF (MNRF)
| Product | Description and capabilities | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Quadessy (spelled "Qudessy"/"Quadsae" in some press) | Hybrid MNRF combining invasive microneedle and non-invasive RF delivery | Clinics treating texture, scars, laxity | Launched Jul 2025. An improved version reflecting customer feedback was relaunched in Korea in 2Q26. | Management target above 1,000 units a year as global rollout proceeds. Korean sales were weak in 1H26, with domestic sales paused and then resumed in 2Q26 (Kiwoom, Jul 2026; IR Book 2Q26). US sales progressing per Kiwoom (Aug 2026). |
| Secret series (Ilooda legacy, e.g. Secret RF) | Fractional MNRF platform | Dermatology clinics, mainly US and Europe pre-merger | Pre-merger | More than 5,000 cumulative units before the merger (Medigate News, Jun 2024) |
Lasers
| Product | Description and capabilities | Target customer | Launch / latest | Notes |
|---|---|---|---|---|
| Reepot (Ilooda legacy) | Vascular / pigment laser | Dermatology clinics | Pre-merger | Contributed to Korean device sales in 2025. Created a high base in Korea, which explains part of the 2Q26 device decline (IR Book 2Q26). |
| Fortra | New laser product described by management as a "first kind of laser" | Clinics; combination-procedure protocols | 2025–26 | Used in Korean combination protocols with Volnewmer and Shurink Universe (IR Book 4Q25 guidance slide). Laser sales grew strongly in Europe in 2Q26. |
Consumables
HIFU cartridges: for Shurink, Shurink Universe and Ultraformer, in multiple depths and modes.
RF tips: for Volnewmer/Everesse.
MNRF tips: for Quadessy and the Secret series.
Consumables were 45.9% of FY2025 revenue. In 2Q26, overseas consumables kept growing at more than 30% YoY as the installed base expanded. Korean consumables fell 15.1% YoY because of a high Shurink Universe base and a wider range of competing treatments (IR Book 2Q26).
Homecare and cosmetics (B2C)
| Product / brand | Description | Notes |
|---|---|---|
| Shrink Home "Lift-to-Glow" | At-home beauty device under the Shurink brand | Launched 28 Nov 2025 (IR Book 4Q25). Homecare revenue was KRW 7.3 bn in FY2025 and KRW 3.9 bn in 1H26. |
| Skederm | Home-care device and skincare brand. Earlier products included Touchwave and others. | Asia Economy, Oct 2020 |
| ShurinkRX / Skederm cosmetics | Post-procedure skincare | KRW 0.9 bn, 1% of 1Q25 revenue (IR Book 1Q25) |
| Cluederm | Aesthetic-shop device brand | About 5.7% of revenue in 2020 (Daishin, 2021). Current contribution not separately disclosed. |
Services
Clinical education: Classys Academy and MedSystems Academy in Brazil. The Classys Global Customer Summit in Japan (Nov 2025) had about 150 Asian physicians.
Customer financing and education services: through JL Health's non-distribution subsidiaries in Brazil (MedSystems IR Book).
Device rentals: in Korea (KRW 0.9 bn in FY2025).
Financial Narrative
Income statement
Sources: Revenue, OP and net income for FY2021–25 from the DART-derived summary on Butler.works and IR Book 4Q25. Gross profit, EBITDA and pre-tax for FY2024–25 from IR Book 4Q25. FY2023 EBITDA is derived from the 52% EBITDA margin cited in the Quartr summary of 2Q24 materials.
Sources: EPS from the Kiwoom Securities report, 16 Jul 2026. FY2025 DPS from the Quartr 1H26 summary and Samsung Securities (payout 49.4%, total KRW 65.2 bn).
Derived. Revenue CAGR FY2021–25 is 35.3%, which matches the company's own 35% (IR Book 4Q25).
Commentary. Over FY2021–25 revenue grew 3.3x while operating margin stayed between 48.6% and 51.4%. Few listed medical-device companies have done this. Margin resilience came from (1) the rising consumables share, (2) cost-down programmes on core devices, which management targets at a 20% unit-cost reduction (merger release, Oct 2024), and (3) operating leverage on a lean HQ of about 530 people. Gross margin fell 1.2 points in FY2025 because devices took a larger share of the mix and lower-margin Ilooda products rose to 15% of revenue. Tighter SG&A (26.9% of revenue, down from 28.3%) and a bad-debt reversal on Brazilian receivables in 4Q25 offset this. Below the operating line, FY2025 net income benefited from a sharply lower effective tax rate: tax expense was KRW 13.3 bn on pre-tax KRW 168.7 bn, about 7.9%, against about 23.5% in FY2024. Management did not explain the cause in the materials reviewed. That benefit will not recur in FY2026: 1H26 tax was KRW 22.8 bn on KRW 81.5 bn pre-tax, about 28%.
Quarterly trajectory (the 2026 inflection)
Sources: IR Books 1Q25, 3Q25, 4Q25 and 2Q26. 1Q25 EBITDA and net income are derived from 1H25 totals minus 2Q25. Yonhap reported 2Q26 net income of KRW 25.5 bn (−3.6% YoY) from the preliminary filing, while the IR Book shows KRW 28.4 bn attributable. The difference is most likely the definition (total vs attributable, or preliminary vs final) and should be reconciled against the half-year report.
Commentary. 1Q26 broke a long run of profit growth: OP fell 4.1% YoY and missed consensus by 15–17% (Kyobo; Eugene). Causes were acquisition fees for MedSystems and China entry, higher marketing, and unrealized-profit elimination on stock shipped to new subsidiaries. In 2Q26 revenue crossed KRW 100 bn for the first time, but OP grew only 2.2% and the operating margin fell 10 points YoY to 41.6%. Korea revenue dropped 25.3% YoY. Revenue has grown YoY for 21 consecutive quarters (Eugene, Aug 2026), but earnings growth has stalled.
Balance sheet
Source: IR Book 4Q25 (FY2022–FY2025) and IR Book 2Q26 (FY2023–Jun-2026). Working capital is derived.
Debt. The only borrowing the company names is an HQ building loan of KRW 61 bn. It sat in non-current liabilities at end-2025 and was reclassified to current by June 2026, meaning it falls due within 12 months. At June 2026 there were also South American borrowings of undisclosed amount (IR Book 2Q26). The company has no bonds outstanding (Kyobo estimates, 2026). Before 2024, the company refinanced short-term debt into long-term (IR Book 4Q25).
Net cash at FY2025 was about KRW 147 bn if the HQ loan is the only borrowing (derived). At June 2026, cash of KRW 136.1 bn less the KRW 61 bn HQ loan gives about KRW 75 bn before South American borrowings.
Goodwill and intangibles rose from KRW 2.8 bn (FY2023) to KRW 140.9 bn (FY2024) with the Ilooda merger, and to KRW 162.6 bn (Jun 2026) with MedSystems goodwill and capitalized clinical costs.
Commentary. Receivables doubled in six months to KRW 98.4 bn because South American receivables were consolidated. MedSystems sells to clinics on instalment terms and provides customer financing services, so consolidated working capital now carries Brazilian consumer and clinic credit risk. Inventories more than doubled to KRW 64.9 bn for the same reason. Cash fell by KRW 71.5 bn in 1H26 after the KRW 65.2 bn FY2025 dividend and the MedSystems purchase. The balance sheet remains strong, with equity at about 72% of assets, but it is no longer the cash-rich, asset-light structure it was before 2024.
Cash flow
Qualitatively, management attributes the rise in cash from KRW 158.0 bn to KRW 207.6 bn during FY2025 to strong operating performance (IR Book 4Q25), despite capex on HQ and plant buildings and the integration of the former Ilooda industrial facility. One reference point: EBITDA of KRW 185.2 bn less an estimated tax of about KRW 13 bn suggests strong underlying cash generation in FY2025. That figure is not a reported free cash flow.
Ratios
All derived from IR Books 4Q25 and 2Q26. ROE and ROA use average balances and parent-attributable net income where available. Financial expenses include FX losses, so the coverage ratio is conservative. Net debt/EBITDA is negative (net cash) in every year shown.
Commentary. ROE of 26–29% on a largely unlevered balance sheet reflects high margins rather than leverage. The FY2024 dip in the current ratio came from short-term borrowings that were later refinanced into long-term debt. The June 2026 reclassification of the HQ loan will compress the ratio again, though liquidity is not under pressure. Inventory days fell sharply in FY2025, which the company attributes to better production management.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Category (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Device revenue | 123.9 | 174.0 |
Device revenue - Global | 94.9 | 128.0 |
Device revenue - Korea | 29.0 | 45.9 |
Consumables revenue | 113.3 | 154.6 |
Consumables revenue - Global | 67.0 | 95.5 |
Consumables revenue - Korea | 46.3 | 59.2 |
Homecare revenue | 4.7 | 7.3 |
Rentals revenue (Korea) | 1.0 | 0.9 |
Total revenue | 242.9 | 336.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCategory growth and mix (%)
| Category growth and mix (%) | FY2024 | FY2025 |
|---|---|---|
Device YoY growth (%) | — | 40.4 |
Consumables YoY growth (%) | — | 36.5 |
Homecare YoY growth (%) | — | 54.5 |
Device share of revenue (%) | 51.0 | 51.7 |
Consumables share of revenue (%) | 46.6 | 45.9 |
Homecare share of revenue (%) | 1.9 | 2.2 |
Segment Revenue
| Category (KRW Bn) | 1H25 | 1H26 |
|---|---|---|
Legacy business total | 160.4 | 175.8 |
Legacy - Global | 105.9 | 130.0 |
Legacy - Korea | 54.5 | 45.8 |
Device | 80.6 | 91.4 |
Device - Global | 58.8 | 77.2 |
Device - Korea | 21.8 | 14.2 |
Consumables | 76.2 | 80.2 |
Consumables - Global | 46.2 | 52.5 |
Consumables - Korea | 30.0 | 27.7 |
Homecare | 3.2 | 3.9 |
Rentals | 0.4 | 0.3 |
South America adds | 0.0 | 16.9 |
Consolidated revenue | 160.4 | 192.7 |
2Q26 profitability (%)
| 2Q26 profitability (%) | Standalone (HQ) | Consolidated |
|---|---|---|
Gross margin | 76.9 | 72.5 |
Operating margin | 50.8 | 41.6 |
Net margin | 42.9 | 26.9 |
EBITDA margin | 55.0 | 45.6 |
Income Statement
| Metric (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 100.6 | 141.8 | 180.1 | 242.9 | 336.8 |
Gross profit | — | — | — | 191.1 | 261.1 |
Operating income | 51.7 | 68.9 | 89.6 | 122.4 | 170.6 |
EBITDA | — | — | 93.7 | 129.7 | 185.2 |
Pre-tax income | — | — | — | 127.9 | 168.7 |
Net income (consolidated) | 43.8 | 75.4 | 74.2 | 97.5 | 132.0 |
Net income attributable to parent | — | — | — | 97.9 | 131.9 |
Per-share metric (KRW)
| Per-share metric (KRW) | FY2024 | FY2025 |
|---|---|---|
Basic EPS | 1,517 | 2,014 |
Dividend per share | — | 1,000 |
Margin (%)
| Margin (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | — | — | — | 78.7 | 77.5 |
Operating margin | 51.4 | 48.6 | 49.8 | 50.4 | 50.7 |
EBITDA margin | — | — | 52.0 | 53.4 | 55.0 |
Net margin | 43.5 | 53.2 | 41.2 | 40.1 | 39.2 |
Revenue growth YoY | — | 41.0 | 27.0 | 34.9 | 38.6 |
Financial Analysis
| Metric (KRW Bn) | 1Q25 | 2Q25 | 3Q25 | 4Q25 | 1Q26 | 2Q26 |
|---|---|---|---|---|---|---|
Revenue | 77.1 | 83.3 | 83.0 | 93.4 | 87.2 | 105.5 |
Gross profit | 61.3 | 64.0 | 63.7 | 72.0 | 65.0 | 76.5 |
Operating income | 38.8 | 43.0 | 37.6 | 51.2 | 37.2 | 43.9 |
EBITDA | 42.3 | 46.7 | 41.3 | 54.9 | 41.0 | 48.1 |
Net income attributable | 29.8 | 26.5 | 33.1 | 42.6 | 33.6 | 28.4 |
Operating margin (%) | 50.3 | 51.6 | 45.3 | 54.8 | 42.7 | 41.6 |
Balance Sheet
| Metric (KRW Bn) | FY2022 | FY2023 | FY2024 | FY2025 | Jun-2026 |
|---|---|---|---|---|---|
Total assets | 331.4 | 375.4 | 608.4 | 704.6 | 774.7 |
Current assets | 147.8 | 185.7 | 234.2 | 295.8 | 317.7 |
Cash and equivalents (incl. ST instruments and FVPL) | 111.6 | 136.9 | 158.0 | 207.6 | 136.1 |
Inventories | 23.4 | 19.4 | 30.0 | 30.1 | 64.9 |
Accounts receivable | 6.9 | 17.3 | 36.9 | 48.4 | 98.4 |
PP&E | 104.2 | 139.0 | 193.2 | 199.7 | 206.0 |
Investment property | 74.7 | 41.1 | 29.4 | 29.3 | 29.2 |
Intangible assets incl. goodwill | 1.5 | 2.8 | 140.9 | 139.6 | 162.6 |
Current liabilities | 36.2 | 29.2 | 128.9 | 80.2 | 198.9 |
Non-current liabilities | 65.6 | 62.7 | 26.8 | 72.9 | 20.7 |
Total liabilities | 101.9 | 91.9 | 155.7 | 153.1 | 219.6 |
Total equity | 229.6 | 283.5 | 452.6 | 551.5 | 555.1 |
Working capital (CA − CL) | 111.6 | 156.5 | 105.3 | 215.6 | 118.8 |
Dividends & Capital Returns
| Metric (KRW Bn) | FY2025 |
|---|---|
Dividend declared for the FY | 65.2 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE (%) | — | 28.9 | 26.6 | 26.3 |
ROA (%) | — | 21.0 | 19.9 | 20.1 |
Current ratio (x) | 4.08 | 6.36 | 1.82 | 3.69 |
Liabilities to equity (x) | 0.44 | 0.32 | 0.34 | 0.28 |
Asset turnover (x) | — | 0.51 | 0.49 | 0.51 |
Receivable days (DSO) | — | 35 | 55 | 52 |
Inventory days (on COGS) | — | — | 211 | 145 |
OP / total financial expenses (x) | — | — | 19.7 | 15.8 |
Revenue by geography (KRW Bn)
| Revenue by geography (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Global (overseas) revenue | 163.6 | 224.7 |
Korea revenue | 79.4 | 112.2 |
Overseas share of revenue (%) | 67.4 | 66.7 |
Region revenue (KRW Bn)
| Region revenue (KRW Bn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Korea | 30.2 | 53.9 | 63.0 | 79.4 | 112.2 |
APAC ex-Korea | 35.2 | 36.9 | 46.8 | 75.3 | 97.7 |
Americas | 15.1 | 29.8 | 48.6 | 55.9 | 57.3 |
EMEA | 19.1 | 19.9 | 21.6 | 34.0 | 70.7 |
Total | 100.6 | 141.8 | 180.1 | 242.9 | 336.8 |
Region growth YoY (%)
| Region growth YoY (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Korea | 78.5 | 16.9 | 26.0 | 41.3 |
APAC ex-Korea | 4.8 | 26.8 | 60.9 | 29.7 |
Americas | 97.4 | 63.1 | 15.0 | 2.5 |
EMEA | 4.2 | 8.5 | 57.4 | 107.9 |
Country revenue (KRW Bn)
| Country revenue (KRW Bn) | FY2024 |
|---|---|
Brazil | 47.1 |
Thailand | 22.0 |
Japan | 14.2 |
Capital Markets
| Measure | Value | Basis / source |
|---|---|---|
Last close | KRW 28,350 | 19 Oct 2026 (AlphaSquare) |
52-week high / low | KRW 77,600 / 26,550 | AlphaSquare |
Drawdown from 52-week high | -63.5% | Derived |
Year to date | about -51% | Against KRW 58,100 on 9 Jan 2026 (Kiwoom); derived |
1-year | about -44% | Against KRW 50,600 on 28 Oct 2025 (Kiwoom); derived |
3-year | about -25% (indicative) | Kiwoom's Nov 2023 initiation implies about KRW 37,000–38,000 at the time; approximate |
Valuation Multiples
| Multiple | CLASSYS | Basis |
|---|---|---|
Market cap (KRW Bn) | 1,849 | 65,235,659 shares × KRW 28,350 |
Enterprise value (KRW Bn) | 1,774 | Market cap less about KRW 75 bn net cash (Jun 2026 cash 136.1 less HQ loan 61; South American borrowings excluded because undisclosed) |
P/E trailing, FY2025 EPS (x) | 14.1 | EPS KRW 2,014 |
P/E LTM (x) | 13.4 | LTM net income about KRW 137.7 bn (2H25 + 1H26) |
P/E 2026E (x) | 12.8 | Daishin 2026E EPS KRW 2,222 (Aug 2026) |
EV/EBITDA LTM (x) | 9.6 | LTM EBITDA KRW 185.3 bn |
EV/Sales LTM (x) | 4.8 | LTM revenue KRW 369.1 bn |
P/B (x) | 3.4 | Jun 2026 equity about KRW 549.5 bn attributable (consistent with the 3.36x on Judal, Oct 2026) |
Dividend yield (%) | 3.5 | FY2025 DPS KRW 1,000 on KRW 28,350 |
Analyst Ratings & Targets
| Broker | Date | Rating | Target (KRW) |
|---|---|---|---|
Daishin | Aug 2026 | Buy | 60,000 (−26%) |
Kiwoom | 13 Aug 2026 | Buy | 54,000 |
Mirae Asset | Aug 2026 | Buy | 64,000 |
Eugene | Aug 2026 | Buy | 67,000 |
Samsung | 22 Jul 2026 | Buy | 70,000 |
Kyobo | 23 Jul 2026 | Buy | 70,000 |
IBK | 23 Jul 2026 | Buy (initiation) | 62,000 |
Dividend metric
| Dividend metric | FY2025 |
|---|---|
DPS (KRW) | 1,000 |
Total dividend (KRW Bn) | 65.2 |
Payout ratio (%) | 49.4 |
Analyst Conclusions
Management guidance
-
FY2026 revenue: KRW 445 bn (revised 12 Aug 2026, from KRW 470–510 bn). This implies 2H26 revenue of about KRW 252 bn, +43% YoY.
-
No explicit FY2026 operating-margin guidance. Standalone OPM is said to remain above 50%.
-
2030: revenue of at least US$1 bn and OPM of at least 50%.
Consensus expectations
| Estimate (KRW Bn) | FY2025A | FY2026E | FY2027E |
|---|---|---|---|
| Revenue, Kiwoom (Jul 2026) | 336.8 | 448.2 | 595.7 |
| Operating income, Kiwoom (Jul 2026) | 170.6 | 208.2 | 283.2 |
| Operating income, Eugene (May 2026) | 170.6 | 217.3 | 277.9 |
| Operating income, Kyobo (May 2026) | 170.6 | 220.8 | 290.2 |
These were mostly published before the 2Q26 guidance cut. Post-cut estimates are likely lower. Eugene's post-2Q26 forecast for 3Q26 is revenue KRW 121.2 bn and OP KRW 59.7 bn.
Bull case
-
The core business is intact. Standalone OPM of 50.8% and GPM of 76.9% in 2Q26 show the HQ franchise has not eroded. The consolidated margin decline is mostly structural dilution from distribution, not price erosion.
-
Overseas growth is broad-based. Legacy global revenue grew 27.6% YoY in 2Q26, with records in Europe, North America and Thailand and Ultraformer's best-ever overseas quarter. This momentum is independent of Korea.
-
The valuation reflects a lot of bad news. About 13x LTM earnings, about 9.6x EV/EBITDA and a 3.5% yield for a company with about 26% ROE. Catalysts include China Volnewmer approval, the US HIFU pivotal readout and a possible change-of-control premium.
Bear case
-
Growth quality is deteriorating. Korea fell 25% in 2Q26, Quadessy needed a relaunch, guidance was cut, and the 2H26 guidance implies a +43% YoY step-up that may itself be at risk.
-
Vertical integration lowers the margin ceiling. MedSystems' EBITDA margin is in the low teens, and Latin American receivables have doubled consolidated AR. The "50% OPM" identity may not return at group level.
-
Overhang and governance. Bain still holds about 46–49%, has sold twice at discounts, carries KRW 930 bn of share-secured holdco debt, and has failed to sell control at its asking price. CEO turnover adds uncertainty.
Catalysts and monitorables (next 12 months)
-
3Q26 results (expected around mid-November 2026): Korean recovery, South American top line, consolidated OPM.
-
Delivery against the KRW 445 bn FY2026 guidance (FY results around Feb 2027) and the FY2027 guidance.
-
Volnewmer NMPA (China) approval, expected around Dec 2026, and first shipments.
-
Progress and readout of the Ultraformer MPT PLUS IDE study; timing of the FDA submission.
-
Any Bain transaction: control sale, further block sales, or holdco refinancing stress.
-
The new team's strategy (CEO, CTO, CCO): possible AI/data product roadmap and an investor day.
-
Receivable days and bad-debt trends in South America.
-
FY2026 dividend and buyback decisions, which support the yield-based floor.
Analyst verdict
CLASSYS is two companies on one ticker. The first is a highly profitable Korean device-and-consumables franchise. It still earns about 51% operating margins at the parent level, keeps growing overseas consumables above 30% a year, and has a deep HIFU installed base that few rivals can match on unit economics. The second is a company in transition. It is spending to become a vertically integrated global aesthetics platform through Brazilian distribution, direct sales in Japan, US and China entry, and an AI agenda. A newly assembled leadership team, including a Samsung strategist CEO, a former Bain & Company partner as CCO and a SAIT-trained CTO, runs it under a private-equity owner that has spent two years trying to exit.
The market has shifted from valuing the first company to doubting the second. A 64% drawdown, a guidance cut, two quarters of earnings misses and three CEOs in eight months together justify a lower multiple. At about 13x trailing earnings and under 10x EV/EBITDA, however, the shares now price CLASSYS below a mature Korean peer such as Wontech on some measures, despite superior margins and scale.
The investment case therefore rests less on 2026 numbers and more on evidence over the next two to four quarters. Investors need to see Korean revenue stabilise and South American revenue grow at margins that rebuild consolidated operating margin toward the mid-40s. They also need confirmation of the China and US regulatory milestones. If 3Q–4Q26 show a credible path to the revised guidance and China approval arrives on time, the valuation gap and a possible Bain-driven change-of-control process give asymmetric upside. If the 2H26 ramp falls short, further estimate cuts and continued overhang could keep the stock range-bound despite strong free-cash characteristics. Stance: cautiously constructive on a 12–18-month view, with high execution risk. The near term depends on the 3Q26 print and the FY2027 guidance.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Age | Source |
|---|---|---|---|---|---|
Yoon Jun-oh | Representative Executive Officer and CEO | Since 15 Jul 2026 | Former EVP, Samsung Electronics. Software engineer, marketing and planning roles at Samsung Korea and US. Samsung Group Future Strategy Office strategy team 2009–18, covering portfolio strategy and large M&A. Helped lead the Harman acquisition and integration. Board seats at Rainbow Robotics and FläktGroup. Engineering background. | Born 1967 | SmartToday; Dealsite; Hankyung, 15 Jul 2026 |
Choi Yun-seok | CFO (전무) | CFO since about 2022; CEO Dec 2025–Jul 2026; returned to CFO Jul 2026 | Former CFO of Gong Cha Korea and ESG Co.; management planning, M&A and accounting | — | Kukinews, Nov 2022; Newsis, Jul 2026 |
Kim Taek-soo | CTO and Head of R&D | Since 4 Aug 2026 | Samsung Advanced Institute of Technology; Vuno (Korean medical AI); Stanford PhD. Experience from technology development through clinical, regulatory approval and commercialisation. | — | Dealsite, 4 Aug 2026; Asia Economy, Oct 2026 |
Bae Jeong-hee | EVP, Chief Commercial Officer, Head of GTM Center | Since Oct 2026 | Korea University; LG CNS systems engineer; Harvard MBA; Monitor Group; Deloitte Consulting; partner at Bain & Company, latterly leading AI and digital strategy. Brand launches and market entry across about 30 countries. | — | Asia Economy, 12 Oct 2026 |
Andrea Gaeta Lima | CEO, MedSystems (Brazil) | Since about Mar 2026 | Former head of Allergan Aesthetics Brazil (AbbVie) | — | Techleap/Edaily, Mar 2026; Times Brasil, Jul 2026 |
Tadashi Yoshikawa | President, Classys Japan | Since Feb–Mar 2025 | Former CEO of HydraFacial Japan and Cynosure Japan; 30+ years at global companies | — | Venture Square, Mar 2025 |
Baek Seung-han | Former CEO | Nov 2022–Dec 2025 | Led the Ilooda merger, US, Europe and Japan entry, and the MedSystems deal | — | Kukinews; Beauty Matter |
Jung Sung-jae | Founder; former CEO and controlling shareholder | 2007–2022 | Dermatologist (Hanyang University BSc/MSc); co-creator of Dr. Jart+. Forbes estimated net worth US$760 m (2025). | Born Oct 1967 | Wikipedia |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake (%) | Date / basis | Source |
|---|---|---|---|
BCPE Centur Investments, LP (Bain Capital) and affiliate | 49.1 | Jul 2026, "BCPE and 1 other" | Kiwoom Securities, 16 Jul 2026 |
BCPE (alternative calculation) | about 45.9 | 54.16% (Feb 2026) less the 8.24% block sale | IB Tomato, Feb 2026; Money Today, Jun 2026 |
Capital Research and Management Company | 6.16 | 27 Jul 2026, 4,020,083 shares, passive investment | Kormedi, citing the large-holding report |
Treasury shares | 0.02 | 2026 | Butler.works |
Foreign ownership, all holders | 67.97 | 8 Oct 2026 | JoongAng Economy News |
Competitive Landscape
Key Competitors
| Competitor | Listing / owner | Overlapping products | Relative positioning vs CLASSYS |
|---|---|---|---|
Merz Aesthetics | Private (Merz Group) | Ultherapy (HIFU), the FDA-cleared US reference device | Premium global HIFU incumbent. CLASSYS's US HIFU trial uses Ulthera as comparator. Revenue not disclosed. |
Solta Medical | Bausch Health subsidiary | Thermage FLX/CPT (monopolar RF) | Premium monopolar RF incumbent. Volnewmer is positioned as an alternative and tested against Thermage CPT. |
InMode | Nasdaq: INMD | Morpheus8 (MNRF), RF platforms | FY2025 revenue US$370.5 m (−6%), GAAP operating margin 23% (InMode FY2025 release). Strong US MNRF presence; competes with Quadessy. |
Sisram Medical (Alma Lasers) | HKEX: 1696 (Fosun) | Lasers, RF, HIFU-adjacent, injectables | FY2025 revenue US$365.3 m (+4.7%); operating income US$27.0 m (Sisram 2025 Annual Report; StockAnalysis). Broad portfolio with lower margins. |
Wontech | KOSDAQ: 336570 | Oligio (monopolar RF), Picocare (laser) | FY2025 revenue KRW 156.8 bn (+36.1%), OP KRW 51.7 bn (Medifo News, 2026). Closest Korean monopolar-RF rival to Volnewmer. Expanding direct sales in Thailand, US, Japan and China. |
Jeisys Medical | — | Potenza (MNRF), Density (RF), Linear Z (HIFU) | Korean multi-modality rival. |
Hironic | — | Doublo (HIFU) | Korean HIFU competitor. |
Cynosure Lutronic | Private (merged entity) | Lasers, RF (e.g. Lutronic devices) | Laser and RF overlap. |
BTL Aesthetics | Private | RF and body/face energy devices | Global device marketer. Financials not publicly disclosed. |
Sofwave Medical | TASE | SUPERB ultrasound lifting | US ultrasound tightening competitor. |
Cutera | — | Lasers and RF | US laser and RF overlap. |
Peer Comparison FY2025
| Company | FY2025 revenue (USD Mn) | Revenue growth (%) | Operating margin (%) | R&D (% of revenue) |
|---|---|---|---|---|
CLASSYS | 236 | 38.6 | 50.7 | 5.2 |
InMode | 370.5 | -6.0 | 23.0 | — |
Sisram Medical | 365.3 | 4.7 | 7.4 | 4.6 |
Wontech | 110 | 36.1 | 33.0 | — |



